Microsoft and Nvidia have announced a collaboration to accelerate healthcare innovation through generative AI and cloud computing.
The partnership involves combining the capabilities of Microsoft Azure with Nvidia DGX Cloud and the Nvidia Clara suite to enhance patient care services.
The corporations will provide pharmaceutical companies and medical device developers with tools to increase efficiency in clinical trials and drug manufacturing.
The collaboration also aims to improve patient services. According to company representatives, it will enable the development and deployment of AI models for visualization, enhancing data processing effectiveness for research and training.
A key phase is the integration of Nvidia BioNeMo into DGX Cloud using Microsoft Azure. This will accelerate the development and testing of neural networks for creating new drugs.
The SOPHiA DDM platform based on Nvidia Parabricks will offer a comprehensive and scalable solution for genome analysis. The initiative is aimed at supporting medical institutions in extracting vital information at the intracellular level.
Microsoft also plans to make Nvidia’s future set of medical services available in Azure AI. This will allow doctors to utilize AI advancements in patient treatment.
Earlier, Tierra Biosciences developed a platform for protein synthesis managed by a neural network.